NG-Monomethyl-L-Arginine

Phase 1Small molecule

NG-Monomethyl-L-Arginine is one of 117 small molecule programs targeting Essential Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

Polycystic Kidney DiseaseActive, not recruiting

Congestive Heart FailureActive, not recruiting

CirrhosisActive, not recruiting

Essential HypertensionPhase 1

Active, not recruiting

Polycystic Kidney DiseasePhase 1

Active, not recruiting

Congestive Heart FailurePhase 1

Active, not recruiting

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Preclinical

2 2

Thalomid

Bristol-Myers Squibb

Preclinical

1 3

Revia

Teva

Preclinical

1 4

Cipro

Bayer

Preclinical

1 5

Dobutrex

Eli Lilly

Preclinical

1 6

Azulfidine

Pfizer

Preclinical

1 7

HEPCLUDEX

Gilead

Preclinical

1 8

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

5 9

Cialis

Eli Lilly

Preclinical

—10

Inderal

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Active, not recruiting

Rehabilitation

NCT03625349

Clinical

Trials by Indication[1]

Nitric Oxide2 trials

Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans

Completed·MMedical University of Vienna·N/A·NCT00806741·18 enrolled

Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure

Withdrawn·MMedical University of Vienna·Phase 2·NCT00406731

Rehabilitation1 trial

Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation

Active, not recruiting·VVA Office of Research and Development··NCT03625349·130 enrolled

Gene Polymorphism1 trial

Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?

Terminated·MMedical University of Vienna·Phase 1·NCT00708357·12 enrolled

Essential Hypertension1 trial

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Completed·RRegional Hospital Holstebro·Phase 1·NCT00345150·30 enrolled

Excretion1 trial

Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones

Unknown status·RRegional Hospital Holstebro·N/A·NCT01617551·30 enrolled

7 more indications

Intraocular Pressure1 trial

Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans

Terminated·MMedical University of Vienna·N/A·NCT00914394·12 enrolled

Polycystic Kidney Disease1 trial

Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis

Completed·RRegional Hospital Holstebro·Phase 1·NCT00345137·75 enrolled

Congestive Heart Failure1 trial

Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure

Completed·RRegional Hospital Holstebro·Phase 1·NCT00344734·30 enrolled

Cirrhosis1 trial

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

Completed·RRegional Hospital Holstebro·Phase 1·NCT00344916·30 enrolled

Hemodynamic1 trial

Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters

Completed·MMedical University of Vienna·N/A·NCT00431665·9 enrolled

CLE1 trial

Plasma Triglyceride Extraction by The Muscle

Completed·MMayo Clinic·Phase 1·NCT01860911·33 enrolled

Unspecified2 trials

Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions

Completed·MMedical University of Vienna·Phase 2·NCT00431392·42 enrolled

L-NMMA Dose-response Study in Healthy Subjects

Completed·RRegional Hospital Holstebro·Phase 1·NCT01070940·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for NG-Monomethyl-L-Arginine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NG-Monomethyl-L-Arginine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NG-Monomethyl-L-Arginine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMedical University of Vienna

NG-Monomethyl-L-Arginine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Nitric Oxide2 trials

Rehabilitation1 trial

Gene Polymorphism1 trial

Essential Hypertension1 trial

Excretion1 trial

Intraocular Pressure1 trial

Polycystic Kidney Disease1 trial

Congestive Heart Failure1 trial

Cirrhosis1 trial

Hemodynamic1 trial

CLE1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News